Sanofi (EPA:SAN)
France
· Delayed Price · Currency is EUR | Market Cap | 116.79B |
| Revenue (ttm) | 45.17B |
| Net Income (ttm) | 6.30B |
| Shares Out | 1.22B |
| EPS (ttm) | 5.04 |
| PE Ratio | 19.28 |
| Forward PE | 11.59 |
| Dividend | 3.92 (4.00%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 143,941 |
| Average Volume | 2,815,364 |
| Open | 96.09 |
| Previous Close | 96.00 |
| Day's Range | 95.96 - 96.77 |
| 52-Week Range | 85.94 - 110.88 |
| Beta | 0.45 |
| RSI | 50.48 |
| Earnings Date | Apr 24, 2025 |
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial StatementsNews
Notable healthcare headlines for the week: Gilead, CVS Health, Sanofi in focus
Stay updated on top pharmaceutical news: Merck's $3.9B SpringWorks deal, Hims & Hers' Wegovy partnership, CVS exiting Obamacare, and FDA updates on key drugs.
Press Release: Annual General Meeting of April 30, 2025
Annual General Meeting of April 30, 2025 Approval of the financial statements for the fiscal year 2024 Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025 Board composi...
Sanofi becomes a pure play pharma after 50% stake sale in Opella
Sanofi (SNY) stock gains as the company transitions to a pure-play biopharma company with a €10B stake sale in Opella, its consumer healthcare business. Read more here.
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
Sanofi and CD&R close Opella transaction, creat e global consumer healthcare leader Paris, April 30, 2025 . Opella today becomes an independent global leader in consumer healthcare, marking a pivotal ...
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
Sanofi (SNY) Q1 2025 Earnings Call Transcript
Sanofi (NASDAQ:SNY) Q4 2024 Earnings Call Transcript Q1 2025 Earnings Conference Call April 25, 2025 7:00 AM ET Company Participants Thomas Kudsk Larsen - Head, Investor Relations Paul Hudson - Chief...
Sanofi 2025 Q1 - Results - Earnings Call Presentation
The following slide deck was published by Sanofi in conjunction with their 2025 Q1 earnings call.
Sanofi proposes annual dividend of €3.92, a hike of 4.26% from prior dividend
Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed
Roche beat first-quarter sales expectations Thursday, while Sanofi's sales report came in mixed. Shares were muted in premarket trades.
EU pharma majors Sanofi, Roche trade flat after reiterated guidance
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug
The pharmaceutical company said the profit was driven by a higher gross margin and slower operating expense growth.
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug
Sanofi beats top-line and bottom-line estimates; reaffirms FY25 outlook
Sanofi's quarterly profit beats estimates on Dupixent boost, newer products
France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug Dupixent, as well as newer treatments and vaccines.
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER 1 and business EPS 2 of €1.79 Pharma launches reached sales of €0.8 billion, up 43.8%, dr...
Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs
The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European pharmaceutical giants said in a letter published in the Financial Times on...
Pharma bosses call for higher drug prices in EU to counter tariff threat
Novartis and Sanofi CEOs push for European benchmark against US prices
Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition
The U.S. Food and Drug Administration approved the extended use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and...
Earendil Labs and Sanofi partner for two bispecific antibodies
Earendil Labs partners with Sanofi for AI-powered bispecific antibodies targeting autoimmune and bowel diseases. Read more here.
Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study
Sanofi SA (NASDAQ: SNY) on Tuesday shared progress from its mid- to late-stage respiratory pipeline . The French drug maker reported preliminary results from the TIDE-Asthma phase 2 study of amliteli...
Sanofi flunks mid-stage trial for asthma drug
Press Release: Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig...
Press Release: Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig...